4T1 is a breast cancer cell line derived from the mammary gland tissue of a mouse BALB/c strain. [1] 4T1 cells are epithelial and are resistant to 6-thioguanine. [1] In preclinical research, 4T1 cells have been used to study breast cancer metastasis as they can metastasize to the lung, liver, lymph nodes, brain and bone. [2] [3] The cells are known to be highly aggressive in live tissues. [4]
4T1 cell line was originally isolated by Fred Miller and colleagues as one of four sublines derived from the 410.4 tumor that was isolated from a single spontaneously arising mammary tumor. [5]
4T1 resembles human metastatic triple-negative breast cancer (TNBC) in lack of the expression of estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (HER2). [6] In addition, it was described, that this cell line is poorly immunogenic in mice, which corresponds to the characteristics of human mammary adenocarcinoma and leads to the higher tumorigenicity and invasiveness of this breast cancer model. [1]
To understand the pathogenesis of cancer patients, it is necessary to have model systems that faithfully mimic this condition. The application of a murine cancer cell line, such as 4T1, in a mouse model is of great value for preclinical TNBC studies. The 4T1 cell line is widely used as a syngeneic model for human triple-negative breast cancer, which is responsible for more than 17% of breast cancers diagnosed worldwide each year. [7] 4T1 cells can be transplanted into the fat pad of the murine mammary gland, where they are highly tumorigenic, invasive, and spontaneously metastasize to distant organs such as the lungs, liver, lymph nodes, brain, and bone. [1]
4T1 cells grow in 37 °C with 95% air and 5% of carbon dioxide (CO
2). Their average doubling time is 14 hours. The base medium for this cell line is RPMI-1640 Medium with a fetal bovine serum in a final concentration of 10%. 4T1 cells should not be allowed to become 100% confluent. Subculturing at 80% confluence is recommended. For detaching the cells from the surface, rinsing with 0.25% trypsin-0.53mM EDTA solution at room temperature is used. Complete growth medium 95% with DMSO 5% is used as a freezing medium and cells are stored at liquid nitrogen vapor phase temperature. [8]
| CVCL_0125 (4T1) |
| CVCL_QZ56 (4T1-eGFP-Puro) |
| CVCL_QZ59 (4T1-Fluc-Neo/iRFP-Puro) |
| CVCL_L899 (4T1-luc2) |
| CVCL_QZ61 (4T1-mNIS (monoclonal)) |
| CVCL_QZ64 (4T1-mNIS-Puro) |
| CVCL_5I85 (4T1-Red-FLuc-GFP) |
| CVCL_GR31 (4T1.13) |
| CVCL_XG69 (4T1/GFP/FlucII) |
| CVCL_QZ57 (4T1-Fluc-Neo) |
| CVCL_QZ60 (4T1-iRFP-Puro) |
| CVCL_5J28 (4T1-luc2-GFP) |
| CVCL_QZ62 (4T1-mNIS-Neo/eGFP-Puro) |
| CVCL_QZ65 (4T1-mNIS-Puro/Fluc-Neo) |
| CVCL_HE47 (4T1-S) [9] |
| CVCL_GR32 (4T1.2) |
| CVCL_QZ58 (4T1-Fluc-Neo/eGFP-Puro) |
| CVCL_J239 (4T1-Luc) |
| CVCL_5J46 (4T1-luc2-tdTomato) |
| CVCL_QZ63 (4T1-mNIS-Neo/iRFP-Puro) |
| CVCL_5I84 (4T1-Red-FLuc) |
| CVCL_5J45 (4T1-tdTomato) |
| CVCL_JG34 (4T1/CMV-Luc #6) |
Mouse mammary tumor virus (MMTV) is a milk-transmitted retrovirus like the HTL viruses, HI viruses, and BLV. It belongs to the genus Betaretrovirus. MMTV was formerly known as Bittner virus, and previously the "milk factor", referring to the extra-chromosomal vertical transmission of murine breast cancer by adoptive nursing, demonstrated in 1936, by John Joseph Bittner while working at the Jackson Laboratory in Bar Harbor, Maine. Bittner established the theory that a cancerous agent, or "milk factor", could be transmitted by cancerous mothers to young mice from a virus in their mother's milk. The majority of mammary tumors in mice are caused by mouse mammary tumor virus.
LNCaP cells are a cell line of human cells commonly used in the field of oncology. LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old caucasian male in 1977. They are adherent epithelial cells growing in aggregates and as single cells.
Cancer stem cells (CSCs) are cancer cells that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample. CSCs are therefore tumorigenic (tumor-forming), perhaps in contrast to other non-tumorigenic cancer cells. CSCs may generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Such cells are hypothesized to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. Therefore, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially for patients with metastatic disease.
A mammary tumor is a neoplasm originating in the mammary gland. It is a common finding in older female dogs and cats that are not spayed, but they are found in other animals as well. The mammary glands in dogs and cats are associated with their nipples and extend from the underside of the chest to the groin on both sides of the midline. There are many differences between mammary tumors in animals and breast cancer in humans, including tumor type, malignancy, and treatment options. The prevalence in dogs is about three times that of women. In dogs, mammary tumors are the second most common tumor over all and the most common tumor in female dogs with a reported incidence of 3.4%. Multiple studies have documented that spaying female dogs when young greatly decreases their risk of developing mammary neoplasia when aged. Compared with female dogs left intact, those spayed before puberty have 0.5% of the risk, those spayed after one estrous cycle have 8.0% of the risk, and dogs spayed after two estrous cycles have 26.0% of the risk of developing mammary neoplasia later in life. Overall, unspayed female dogs have a seven times greater risk of developing mammary neoplasia than do those that are spayed. While the benefit of spaying decreases with each estrous cycle, some benefit has been demonstrated in female dogs even up to 9 years of age. There is a much lower risk in male dogs and a risk in cats about half that of dogs.
The prolactin receptor (PRLR) is a type I cytokine receptor encoded in humans by the PRLR gene on chromosome 5p13-14. It is the receptor for prolactin (PRL). The PRLR can also bind to and be activated by growth hormone (GH) and human placental lactogen (hPL). The PRLR is expressed in the mammary glands, pituitary gland, and other tissues. It plays an important role in lobuloalveolar development of the mammary glands during pregnancy and in lactation.
Triple-negative breast cancer (TNBC) is any breast cancer that lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.
Single-minded homolog 2 is a protein that in humans is encoded by the SIM2 gene. It plays a major role in the development of the central nervous system midline as well as the construction of the face and head.
Metastasis-associated protein MTA3 is a protein that in humans is encoded by the MTA3 gene. MTA3 protein localizes in the nucleus as well as in other cellular compartments MTA3 is a component of the nucleosome remodeling and deacetylate (NuRD) complex and participates in gene expression. The expression pattern of MTA3 is opposite to that of MTA1 and MTA2 during mammary gland tumorigenesis. However, MTA3 is also overexpressed in a variety of human cancers.
MCF-7 is a breast cancer cell line isolated in 1970 from a 69-year-old White woman. MCF-7 is the acronym of Michigan Cancer Foundation-7, referring to the institute in Detroit where the cell line was established in 1973 by Herbert Soule and co-workers. The Michigan Cancer Foundation is now known as the Barbara Ann Karmanos Cancer Institute.ESRAA AHMED
Lewis lung carcinoma is a tumor that spontaneously developed as an epidermoid carcinoma in the lung of a C57BL mouse. It was discovered in 1951 by Dr. Margaret Lewis of the Wistar Institute and became one of the first transplantable tumors.
Murine polyomavirus is an unenveloped double-stranded DNA virus of the polyomavirus family. The first member of the family discovered, it was originally identified by accident in the 1950s. A component of mouse leukemia extract capable of causing tumors, particularly in the parotid gland, in newborn mice was reported by Ludwik Gross in 1953 and identified as a virus by Sarah Stewart and Bernice Eddy at the National Cancer Institute, after whom it was once called "SE polyoma". Stewart and Eddy would go on to study related polyomaviruses such as SV40 that infect primates, including humans. These discoveries were widely reported at the time and formed the early stages of understanding of oncoviruses.
The S100 calcium-binding protein mS100a7a15 is the murine ortholog of human S100A7 (Psoriasin) and human S100A15 (Koebnerisin). mS100a7a15 is also known as S100a15, mS100a7 and mS100a7a and is encoded by the mS100a7a gene
The tumor microenvironment (TME) is the environment around a tumor, including the surrounding blood vessels, immune cells, fibroblasts, signaling molecules and the extracellular matrix (ECM). The tumor and the surrounding microenvironment are closely related and interact constantly. Tumors can influence the microenvironment by releasing extracellular signals, promoting tumor angiogenesis and inducing peripheral immune tolerance, while the immune cells in the microenvironment can affect the growth and evolution of cancerous cells.
Patient derived xenografts (PDX) are models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient or humanized mouse. It is a form of xenotransplantation. PDX models are used to create an environment that allows for the continued growth of cancer after its removal from a patient. In this way, tumor growth can be monitored in the laboratory, including in response to potential therapeutic options. Cohorts of PDX models can be used to determine the therapeutic efficiency of a therapy against particular types of cancer, or a PDX model from a specific patient can be tested against a range of therapies in a 'personalized oncology' approach.
Breast cancer metastatic mouse models are experimental approaches in which mice are genetically manipulated to develop a mammary tumor leading to distant focal lesions of mammary epithelium created by metastasis. Mammary cancers in mice can be caused by genetic mutations that have been identified in human cancer. This means models can be generated based upon molecular lesions consistent with the human disease.
Axelopran is a drug which is under development by Theravance Biopharma and licensed to Glycyx for all indications. It acts as a peripherally acting μ-opioid receptor antagonist and also acts on κ-, and δ-opioid receptors, with similar affinity for the μ- and κ-opioid receptors and about an order of magnitude lower affinity for the δ-opioid receptor. Recent data suggests that μ-opioid antagonists have a direct effect on overall survival in patients with advanced cancer.
B16 melanoma is a murine tumor cell line used for research as a model for human skin cancers. B16 cells are useful models for the study of metastasis and solid tumor formation, and were one of the first effective murine tools for metastasis research.
TS/A is a mouse mammary adenocarcinoma cell line established in the early 1980s from a spontaneous tumor of a retired breeder BALB/c female mouse. In the 1990s it was widely used as a recipient cell line for the transduction of cytokine genes and other genes of immunological interest, to produce recombinant experimental vaccines that induced anti-tumor immunological responses.
Breast cancer is the most prevalent type of cancer among women globally, with 685,000 deaths recorded worldwide in 2020. The most commonly used treatment methods for breast cancer include surgery, radiotherapy and chemotherapy. Some of these treated patients experience disease relapse and metastasis. The aggressive progression and recurrence of this disease has been attributed the presence of a subset of tumor cells known as breast cancer stem cells (BCSCs). These cells possess the abilities of self-renewal and tumor initiation, allowing them to be drivers of metastases and tumor growth. The microenvironment in which these cells reside is filled with residential inflammatory cells that provide the needed signaling cues for BCSC-mediated self-renewal and survival. The production of cytokines allows these cells to escape from the primary tumor and travel through the circulation to distant organs, commencing the process of metastasis. Due to their significant role in driving disease progression, BCSCs represent a new target by which to treat the tumor at the source of metastasis.
Mammary secretory carcinoma (MSC), also termed secretory carcinoma of the breast, is a rare form of the breast cancers. MSC usually affects women but in a significant percentage of cases also occurs in men and children. Indeed, McDvitt and Stewart first described MSC in 1966 and termed it juvenile breast carcinoma because an increased number of cases were at that time diagnosed in juvenile females. MSC is the most common form of breast cancer in children, representing 80% of childhood breast cancers, although it accounts for less than 0.15% of all breast cancers.